215 related articles for article (PubMed ID: 11372046)
1. Gemcitabine in advanced bladder cancer.
von der Maase H
Semin Oncol; 2001 Apr; 28(2 Suppl 7):11-4. PubMed ID: 11372046
[TBL] [Abstract][Full Text] [Related]
2. Current and future perspectives in advanced bladder cancer: is there a new standard?
von der Maase H
Semin Oncol; 2002 Feb; 29(1 Suppl 3):3-14. PubMed ID: 11894002
[TBL] [Abstract][Full Text] [Related]
3. Gemcitabine and cisplatin versus methotrexate, vinblastine, doxorubicin, and cisplatin in advanced or metastatic bladder cancer: results of a large, randomized, multinational, multicenter, phase III study.
von der Maase H; Hansen SW; Roberts JT; Dogliotti L; Oliver T; Moore MJ; Bodrogi I; Albers P; Knuth A; Lippert CM; Kerbrat P; Sanchez Rovira P; Wersall P; Cleall SP; Roychowdhury DF; Tomlin I; Visseren-Grul CM; Conte PF
J Clin Oncol; 2000 Sep; 18(17):3068-77. PubMed ID: 11001674
[TBL] [Abstract][Full Text] [Related]
4. Randomized Phase III Trial of Dose-dense Methotrexate, Vinblastine, Doxorubicin, and Cisplatin, or Gemcitabine and Cisplatin as Perioperative Chemotherapy for Patients with Muscle-invasive Bladder Cancer. Analysis of the GETUG/AFU V05 VESPER Trial Secondary Endpoints: Chemotherapy Toxicity and Pathological Responses.
Pfister C; Gravis G; Fléchon A; Soulié M; Guy L; Laguerre B; Mottet N; Joly F; Allory Y; Harter V; Culine S;
Eur Urol; 2021 Feb; 79(2):214-221. PubMed ID: 32868138
[TBL] [Abstract][Full Text] [Related]
5. Gemcitabine for unresectable, locally advanced or metastatic bladder cancer.
Shelley M; Cleves A; Wilt TJ; Mason M
Cochrane Database Syst Rev; 2011 Apr; (4):CD008976. PubMed ID: 21491413
[TBL] [Abstract][Full Text] [Related]
6. Comparative effectiveness of gemcitabine plus cisplatin versus methotrexate, vinblastine, doxorubicin, plus cisplatin as neoadjuvant therapy for muscle-invasive bladder cancer.
Galsky MD; Pal SK; Chowdhury S; Harshman LC; Crabb SJ; Wong YN; Yu EY; Powles T; Moshier EL; Ladoire S; Hussain SA; Agarwal N; Vaishampayan UN; Recine F; Berthold D; Necchi A; Theodore C; Milowsky MI; Bellmunt J; Rosenberg JE;
Cancer; 2015 Aug; 121(15):2586-93. PubMed ID: 25872978
[TBL] [Abstract][Full Text] [Related]
7. Long-term survival results of a randomized trial comparing gemcitabine plus cisplatin, with methotrexate, vinblastine, doxorubicin, plus cisplatin in patients with bladder cancer.
von der Maase H; Sengelov L; Roberts JT; Ricci S; Dogliotti L; Oliver T; Moore MJ; Zimmermann A; Arning M
J Clin Oncol; 2005 Jul; 23(21):4602-8. PubMed ID: 16034041
[TBL] [Abstract][Full Text] [Related]
8. Prospective, open-label, randomized, phase III study of two dose-dense regimens MVAC versus gemcitabine/cisplatin in patients with inoperable, metastatic or relapsed urothelial cancer: a Hellenic Cooperative Oncology Group study (HE 16/03).
Bamias A; Dafni U; Karadimou A; Timotheadou E; Aravantinos G; Psyrri A; Xanthakis I; Tsiatas M; Koutoulidis V; Constantinidis C; Hatzimouratidis C; Samantas E; Visvikis A; Chrisophos M; Stravodimos K; Deliveliotis C; Eleftheraki A; Pectasides D; Fountzilas G; Dimopoulos MA
Ann Oncol; 2013 Apr; 24(4):1011-7. PubMed ID: 23136231
[TBL] [Abstract][Full Text] [Related]
9. Long-term survival results of a randomized trial comparing gemcitabine/cisplatin and methotrexate/vinblastine/doxorubicin/cisplatin in patients with locally advanced and metastatic bladder cancer.
Roberts JT; von der Maase H; Sengeløv L; Conte PF; Dogliotti L; Oliver T; Moore MJ; Zimmermann A; Arning M
Ann Oncol; 2006 May; 17 Suppl 5():v118-22. PubMed ID: 16807438
[TBL] [Abstract][Full Text] [Related]
10. Treatment of metastatic urothelial cancer in the post-MVAC era.
Cohen EE; Stadler WM
World J Urol; 2001 Apr; 19(2):126-32. PubMed ID: 11374315
[TBL] [Abstract][Full Text] [Related]
11. An economic analysis comparing health care resource use and cost of dose-dense methotrexate, vinblastine, doxorubicin, and cisplatin versus gemcitabine and cisplatin as neoadjuvant therapy for muscle invasive bladder cancer.
Montazeri K; Dranitsaris G; Thomas JD; Curran C; Preston MA; Steele GS; Kilbridge KL; Mantia C; Ravi P; McGregor BA; Mossanen M; Sonpavde G
Urol Oncol; 2021 Dec; 39(12):834.e1-834.e7. PubMed ID: 34162500
[TBL] [Abstract][Full Text] [Related]
12. Gemcitabine/cisplatin versus methotrexate/vinblastine/doxorubicin/cisplatin for muscle-invasive bladder cancer: A systematic review and meta-analysis.
Yu C; Hequn C; Jinbo C; Feng Z; Xiongbing Z; Jian D
J Cancer Res Ther; 2018; 14(6):1260-1265. PubMed ID: 30488841
[TBL] [Abstract][Full Text] [Related]
13. [Relative efficacy of neoadjuvant gemcitabine and cisplatin versus methotrexate, vinblastine, adriamycin, and cisplatin in the management for muscle-invasive bladder cancer].
Kawamura N; Matsushita M; Okada T; Ujike T; Nin M; Tsujihata M
Hinyokika Kiyo; 2013 May; 59(5):277-81. PubMed ID: 23719134
[TBL] [Abstract][Full Text] [Related]
14. Neoadjuvant induction dose-dense MVAC for muscle invasive bladder cancer: efficacy and safety compared with classic MVAC and gemcitabine/cisplatin.
van de Putte EE; Mertens LS; Meijer RP; van der Heijden MS; Bex A; van der Poel HG; Kerst JM; Bergman AM; Horenblas S; van Rhijn BW
World J Urol; 2016 Feb; 34(2):157-62. PubMed ID: 26184106
[TBL] [Abstract][Full Text] [Related]
15. Multicenter assessment of neoadjuvant chemotherapy for muscle-invasive bladder cancer.
Zargar H; Espiritu PN; Fairey AS; Mertens LS; Dinney CP; Mir MC; Krabbe LM; Cookson MS; Jacobsen NE; Gandhi NM; Griffin J; Montgomery JS; Vasdev N; Yu EY; Youssef D; Xylinas E; Campain NJ; Kassouf W; Dall'Era MA; Seah JA; Ercole CE; Horenblas S; Sridhar SS; McGrath JS; Aning J; Shariat SF; Wright JL; Thorpe AC; Morgan TM; Holzbeierlein JM; Bivalacqua TJ; North S; Barocas DA; Lotan Y; Garcia JA; Stephenson AJ; Shah JB; van Rhijn BW; Daneshmand S; Spiess PE; Black PC
Eur Urol; 2015 Feb; 67(2):241-9. PubMed ID: 25257030
[TBL] [Abstract][Full Text] [Related]
16. Gemcitabine in the treatment of bladder cancer.
Ryan CW; Vogelzang NJ
Expert Opin Pharmacother; 2000 Mar; 1(3):547-53. PubMed ID: 11249537
[TBL] [Abstract][Full Text] [Related]
17. Retrospective analysis of clinical outcomes with neoadjuvant cisplatin-based regimens for muscle-invasive bladder cancer.
Pal SK; Ruel NH; Wilson TG; Yuh BE
Clin Genitourin Cancer; 2012 Dec; 10(4):246-50. PubMed ID: 22981208
[TBL] [Abstract][Full Text] [Related]
18. Neoadjuvant gemcitabine plus carboplatin for locally advanced bladder cancer.
Iwasaki K; Obara W; Kato Y; Takata R; Tanji S; Fujioka T
Jpn J Clin Oncol; 2013 Feb; 43(2):193-9. PubMed ID: 23275643
[TBL] [Abstract][Full Text] [Related]
19. Phase III trial of cisplatin/gemcitabine with or without vinorelbine or paclitaxel in advanced non-small cell lung cancer.
Comella P;
Semin Oncol; 2001 Apr; 28(2 Suppl 7):7-10. PubMed ID: 11372045
[TBL] [Abstract][Full Text] [Related]
20. Relative efficacy of perioperative gemcitabine and cisplatin versus methotrexate, vinblastine, adriamycin, and cisplatin in the management of locally advanced urothelial carcinoma of the bladder.
Yeshchina O; Badalato GM; Wosnitzer MS; Hruby G; RoyChoudhury A; Benson MC; Petrylak DP; McKiernan JM
Urology; 2012 Feb; 79(2):384-90. PubMed ID: 22196406
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
